(CNN)Two Pfizer and BioNTech Covid-19 vaccine boosters updated to target the Omicron variant With the current Covid-19 vaccine,said on Saturday.
Both companies have targeted vaccines for the Omicron BA.1 subvariant and bivalent boosters, including the current Pfizer / BioNTech Covid-19 vaccine and vaccine candidates targeting Omicron (2). Targeting one strain) was tested.
This study examined two different dose levels (30 micrograms and 60 micrograms) in more than 1,200 adults aged 56 years and older. The current primary and booster doses for this age group are 30 micrograms.
This study showed that at both dose levels, the fourth booster with the Omicron modified vaccine candidate resulted in a substantially higher immune response to the mutant. One month after injection, the monovalent vaccine showed a 13.5-fold and 19.6-fold increase in antibodies that fight Omicron, depending on the dose. The bivalent vaccine showed a 9.1-fold and 10.9-fold increase over the antibody.
Preliminary results from laboratory studies also suggest that the vaccine may neutralize Omicron BA.4 and BA.5, the two companies said. BA.4 and BA. Five subvariants are increasingly in circulation in the United States.
Both vaccine candidates appeared to be safe and tolerable.
Results have been shared in news releases and have not yet been peer-reviewed or published.
"Based on these data, we believe there are two very strong candidates for Omicron modification that elicit a significantly higher immune response to Omicron than we have ever seen," said Pfizer. Albert Bourla, also and Chief Executive Officer, said. In a news release.
